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Abstract: Bipolar depression is more common, disabling, and diffi cult-to-treat than the manic 
and hypomanic phases that defi ne bipolar disorder. Unlike the treatment of so-called “unipolar” 
depressions, antidepressants generally are not indicated as monotherapies for bipolar depressions 
and recent studies suggest that -even when used in combination with traditional mood stabiliz-
ers – antidepressants may have questionable value for bipolar depression. The current practice 
is that mood stabilizers are initiated fi rst as monotherapies; however, the antidepressant effi cacy 
of lithium and valproate is modest at best. Within this context the role of atypical antipsychotics 
is being evaluated. The combination of olanzapine and the antidepressant fl uoxetine was the 
fi rst treatment to receive regulatory approval in the US specifi cally for bipolar I depression. 
Quetiapine was the second medication to be approved for this indication, largely as the result 
of two pivotal trials known by the acronyms of BOLDER (BipOLar DEpRession) I and II. 
Both studies demonstrated that two doses of quetiapine (300 mg and 600 mg given once daily 
at bedtime) were signifi cantly more effective than placebo, with no increased risk of patients 
switching into mania. Pooling the two studies, quetiapine was effective for both bipolar I and 
bipolar II depressions and for patients with (and without) a history of rapid cycling. The two 
doses were comparably effective in both studies. Although the effi cacy of quetiapine mono-
therapy has been established, much additional research is necessary. Further studies are needed 
to more fully investigate dose-response relationships and comparing quetiapine monotherapy to 
other mood stabilizers (lithium, valproate, and lamotrigine) in bipolar depression, both singly 
and in combination. Head-to-head studies are needed comparing quetiapine to the olanzapine-
fl uoxetine combination. Longer-term studies are needed to confi rm the persistence of response 
and to better gauge effects on metabolic profi les across months of therapy. A prospective study 
of patients specifi cally seeking treatment for rapid cycling and those with a history of treat-
ment-emergent affective shifts also is needed. Despite the caveats, as treatment guidelines are 
revised to incorporate new data, the effi cacy and tolerability of quetiapine monotherapy must 
be given serious consideration.
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Introduction
Bipolar disorder is a highly recurrent and not infrequently chronic illness that is 
recognized as one of the world’s 10 greatest public health problems (Murray and 
Lopez 1997). For the majority of patients, the periods of depression far exceed those 
of mania, in terms of both frequency and duration (Post et al 2003; Judd et al 2002, 
2003). For individuals with bipolar I disorder, for example, days spent with depres-
sive symptoms are about three times more common than days spent with hypomanic 
or manic symptoms (Judd et al 2002). The dominance of the depressed pole of the 
illness is even more dramatic individuals with bipolar II disorder: in one prospective 
study conducted across nearly 13 years, patients with bipolar II disorder spent almost 
40 times the days with depressive symptoms as compared to the days spent with 
hypomanic symptoms (Judd et al 2003).
Despite the dramatic and life-disrupting nature of mania, recent studies have also 
documented that it is the more long-lasting depressive episodes that have the greater 
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deleterious effects on quality of life and functionality (Judd 
et al 2005; Depp et al 2006). The burden imposed by bipolar 
depression on the family and loved ones exceeds that of 
bipolar mania or unipolar depression, perhaps all the more 
remarkable in view of the greater risk of psychosis, violent 
behaviour, and increased frequency of hospitalization associ-
ated with mania (Post 2005; Hirschfeld 2004). The perceived 
stigma of the condition may also add to the burden placed 
on the family or primary caregiver (Perlick et al 2004). 
The assessment of caregiver burden is further impeded by the 
unique characteristics of bipolar depression – including the 
unfortunate tendency for milder episodes to go unrecog-
nized or untreated and the high incidence of subsyndromal 
inter-episode symptoms (Ogilvie et al 2005). Perhaps not 
surprisingly, the depressive episodes also are more directly 
linked to reduced longevity in bipolar disorder, particularly 
through suicide but perhaps also to increased risks of obesity 
and cardiovascular disease (Dilsaver et al 1997; Fagiolini 
et al 2002; Mitchell and Malhi 2004).
Despite the obvious clinical importance of the depressed 
phase of bipolar disorder, remarkably few controlled studies 
of fi rst- and second-line treatments have been performed 
(Thase 2005). The paucity of well-designed studies essen-
tially precludes the practice of evidence-based medicine and 
for some important questions (eg, “If an antidepressant is 
used and appears to be effective, how long should it be main-
tained?”) there is not consensus about best practices, which 
no doubt hampers clinical decision-making (Thase 2005; 
Ostacher 2006). Indeed, in the largest placebo-controlled 
study of the role of antidepressants in bipolar depression 
conducted to date, the addition of paroxetine or bupropion 
to optimized therapy with mood stabilizers resulted in no 
added benefi t as compared to therapy with mood stabilizers 
alone (Sachs et al 2007). For the prescribing physician, the 
need to swiftly deliver effective pharmacotherapy to lessen 
suffering and minimize functional impairments is paramount, 
and appears to foster the continued use of antidepressants 
in bipolar depression despite the lack of clear-cut evidence 
that they improve outcomes. Nevertheless, the decision to 
initiate therapy with an antidepressant to hasten recovery is 
not without attendant risks, including treatment-emergent 
affective switches (TEAS) or acceleration of cycling and, 
as a result, the ranking of antidepressants in contemporary 
practice guidelines continues to drop in favor of other strate-
gies (Thase 2005; Yatham et al 2006).
Many expert panels recommend initiating mood 
stabilizers alone, ie, before considering whether or not an 
antidepressant is indicated. If one accepts the validity of 
the “mood stabilizer fi rst” strategy, then lithium and three 
anticonvulsants (valproate, carbamazepine, and lamo-
trigine) might be nominated as candidates for fi rst line 
of therapy for bipolar depression (Thase 2005; Grunze 
2005). However, none of these medications is renowned 
for having powerful antidepressant effects (Thase 2005) 
and – primarily for reasons of tolerability and safety – few 
clinicians would use carbamazepine as the fi rst step in a 
treatment algorithm. Even lithium salts, which arguably 
have the best evidence of effi cacy from placebo-controlled 
studies (Zornberg and Pope 1993; Thase and Sachs 2000), 
do not exert particularly robust antidepressant effects 
(Thase 2005). The search for an effective monotherapy for 
bipolar depression thus goes on.
Emerging data suggest that the list of medications that 
are classifi ed as mood stabilizers eventually may need to be 
expanded to include the class of medications known as atypi-
cal antipsychotics. All fi ve of the more widely prescribed 
atypical antipsychotics (in alphabetical order: aripiprazole, 
olanzapine, quetiapine, risperidone, and ziprasidone) have 
established antimanic effi cacy. Consistent with proposed 
criteria to defi ne mood stabilizers (see, for example, Ketter 
and Calabrese 2002; Goodwin and Malhi 2007), atypical 
antipsychotics are unlikely to cause TEAS and two members 
of the class (olanzapine and aripiprazole) have received a 
formal indication for prophylaxis against manic relapse fol-
lowing successful acute therapy. Starting with observations 
from studies that included patients with mixed manic states, 
there is slowly increasing evidence to indicate that atypical 
antipsychotics also have antidepressant effects (Keck 2005; 
Nemeroff 2005). In fact, the fi rst treatment to be approved 
by the United States Food and Drug Administration (FDA) 
specifi cally for bipolar depression is the proprietary com-
bination of olanzapine and the selective serotonin reuptake 
inhibitor (SSRI), fl uoxetine. In the pivotal trials that led to 
that indication, olanzapine monotherapy was also studied and 
found to have intermediate effi cacy: greater than placebo but 
signifi cantly less than the olanzapine-fl uoxetine combination 
(OFC) (Tohen et al 2003).
This review will focus on the second atypical antipsy-
chotic to be systematically studied as a monotherapy for 
bipolar depression, quetiapine. The results of the research 
program that led to the FDA approval of quetiapine mono-
therapy for bipolar depression will be summarized in detail. 
Quetiapine, which is the fi rst – and currently only – monotherapy 
approved by the FDA to treat both the depressive and manic 
episodes associated with bipolar disorder, has been ranked 
as a fi rst-line treatment of bipolar depression in the recently 
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updated treatment guidelines published by the Canadian 
Network for Mood and Anxiety Treatments (CANMAT) 
(Yatham et al 2006).
Effi cacy against depressive 
symptoms
Regulatory approval of quetiapine monotherapy for bipolar 
depression was primarily based on two similar randomized 
controlled trials (RCTs) known by the acronyms BOLDER 
(BipOLar DEpRession) I and II. Both of these 8-week, 
placebo-controlled, double-blind studies compared two doses 
of quetiapine – 300 mg per day and 600 mg per day. Both 
studies used once daily dosing (at bedtime) and the same 
rapid titration schedule, with maximum study dose achieved 
by the 8th day of treatment. Both studies included patients 
with bipolar I and bipolar II depressive episodes and allowed 
otherwise eligible patients with histories of rapid cycling to 
enroll. Both studies used change in the Montgomery-Åsberg 
Depression Rating Scale (MADRS) total score as the primary 
endpoint. Together, the BOLDER I (Calabrese et al 2005) 
and BOLDER II (Thase et al 2006) studies represent the larg-
est placebo-controlled data set to date that includes patients 
with bipolar I and bipolar II depressions. 
BOLDER I enrolled 542 patients meeting DSM-IV criteria 
for a current episode of bipolar I or bipolar II depression, 
according to DSM-IV criteria (Calabrese et al 2005). In order 
to enter the study, outpatients had to score at least 20 on the 
17-item Hamilton Depression Scale (HAM-D17), as well as 
have a score of at least 2 on HAM-D item 1 (depressed mood). 
Pretreatment MADRS scores indicated that the unmedicated 
study group presented with moderate-to-severe levels of 
depressive symptoms (see, for example, Muller et al 2003).
Both doses of quetiapine resulted in signifi cant improve-
ments in MADRS total scores at all time points measured, 
with statistical signifi cance over placebo detected after only 1 
week of treatment (the fi rst assessment point of the study) and 
maintained at every time point thereafter (see Figure 1a). The 
proportion of patients classifi ed as responders to treatment, 
defi ned as a 50% improvement in MADRS total score at 
study endpoint (using the “last observation carried forward 
[LOCF] convention” to estimate the fi nal scores of study 
dropouts) was signifi cantly higher in both groups receiving 
active quetiapine (58% in both groups) than in the group 
randomized to placebo (36%). Remission rates (defi ned as 
a fi nal MADRS total score 12) followed a similar pattern 
(53% for both 300 mg and 600 mg quetiapine, 28% for 
placebo). Individuals treated with either dose of quetiapine 
were faster to respond to treatment and to achieve remission 
than those receiving placebo (median time to response was 
22 days for both doses of quetiapine versus 36 days for 
placebo, and median times to remission were 29, 27, and 
65 days for 300 mg quetiapine, 600 mg quetiapine, and 
placebo, respectively).
The results of the BOLDER II trial (n = 509) fully 
replicated the fi rst study in terms of the primary outcome 
variable, with quetiapine-treated patients displaying signifi -
cantly greater mean improvement in MADRS total scores 
than placebo-treated patients at all time points from Week 
1 onward (Figure 1b) (Thase et al 2006). Response rates for 
both doses of quetiapine monotherapy were also similar to 
those observed in the original study after 8 weeks of treatment 
(60%, 58%, and 45% for the 300 mg, 600 mg, and placebo 
groups, respectively), as were remission rates (52% for both 
groups receiving active quetiapine as compared to 37% for 
the group receiving placebo). Looking across the two stud-
ies, the only appreciable difference was the higher placebo 
response/remission rates observed in BOLDER II, which 
could possibly be attributable to increased expectations from 
physicians and patients alike, in light of the positive fi ndings 
arising from BOLDER I.
In both BOLDER studies, improvements on the second-
ary rater-administered measure, the HAM-D
17
, mirrored those 
reported on the MADRS scale. For example, both groups 
receiving active quetiapine again experienced signifi cantly 
greater mean improvements from Week 1 onward compared 
with the group receiving placebo.
With respect to the impact of quetiapine on specifi c 
depressive symptoms, at study endpoint improvements were 
detected in nine of the 10 individual items in BOLDER I, and 
in nine individual items in BOLDER II. Figure 2 summarizes 
improvements in individual items of the MADRS scale in 
the BOLDER studies. It is important to note that signifi cant 
improvements were observed on the core symptoms of 
depression, including apparent sadness, reported sadness, 
suicidal thoughts, and pessimistic thoughts, in addition to 
improvements in sleep and anxiety.
Effi cacy in patient subgroups
Since the patient populations enrolled in the BOLDER stud-
ies included individuals with both bipolar I and bipolar II 
depression, and those with and without a rapid-cycling dis-
ease course, the results of the BOLDER trials were examined 
to determine if quetiapine was particularly effective – or 
ineffective – in various patient subgroups. Although there 
are important differences between bipolar I and bipolar II 
disorders (as well as between patients who meet criteria for 
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rapid cycling and those who do not) (Yatham et al 2005), 
demonstration that a novel treatment is comparably effective 
across the subgroups could greatly simplify clinical man-
agement. The combined BOLDER data set shows that both 
bipolar I and bipolar II patient groups exhibited signifi cant 
improvements in MADRS total score following treatment 
with either dose of quetiapine (300 mg per day or 600 mg 
per day) compared with placebo (Figure 3).
Figure 1a Least-squares mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at each assessment of outpatients with bipolar I 
or II disorder who experienced a major depressive episode (BOLDER I).
Figure 1b Least-squares mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at each assessment of outpatients with bipolar I 
or II disorder who experienced a major depressive episode (BOLDER II).
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Rapid cycling is associated with a poorer treatment 
response and long-term prognosis, and is associated with 
greater disability and a higher incidence of suicidal behavior 
(Schneck 2006). Currently available antidepressants may 
increase the risk of rapid cycling, and this uncertainty has 
limited their widespread use (Goldberg and Truman 2003). 
Results of a subanalysis of BOLDER I indicated that quetiap-
ine was as effective in patients with a history of rapid cycling 
as among with less frequent episodes (Vieta et al 2007). A 
not yet published analysis of the combined data from the 
Figure 2 Percentage improvement from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) individual items scores in outpatients with bipolar I or II disor-
der (data pooled from BOLDER I and BOLDER II studies; ITT, LOCF).
Figure 3 Least mean squares change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score in outpatients with bipolar I or II disorder (data 
pooled from BOLDER I and BOLDER II studies; ITT, LOCF).
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BOLDER studies echoed this result and demonstrated the 
broad applicability of quetiapine treatment by revealing a 
similar improvement in MADRS total scores in both patients 
with or without rapid cycling (Figure 4). As many experts 
consider antidepressants to be relatively contraindicated in 
rapid cycling because of an extremely high incidence of 
TEAS, the antidepressant activity of quetiapine could be 
partly offset if therapeutic response was associated with 
increased cycling or the induction of hypomania/mania. It is 
thus noteworthy that the rapid cycling patients treated with 
quetiapine in BOLDER I and BOLDER II were no more 
likely to develop hypomania or mania than were patients 
receiving placebo. Although patients were also assessed for 
signs/symptoms of treatment-emergent mood elevation with 
the Young Mania Rating Scale, to date results on this measure 
have not been reported. Nevertheless, as described below, the 
proportion of patients developing diagnosable episodes of 
hypomania or mania was actually higher among those treated 
with placebo than those receiving active quetiapine.
Effi cacy against anxiety symptoms
Anxiety disorders are highly comorbid with bipolar 
disorder and may predispose individuals to intensified 
symptoms, substance abuse, hospitalization, and suicide 
ideations (Gaudiano and Miller 2005; Keller 2006; 
McIntyre et al 2006). A cross-sectional sample from 
500 individuals with bipolar I or II disorder enrolled in the 
Systematic Treatment Enhancement Program for Bipolar 
Disorder (STEP-BD) indicated that comorbid anxiety disor-
ders, which were identifi ed in over half of the sample, had a 
large and negative impact on role functioning and quality of 
life (Simon et al 2004a). The patient’s response to treatment 
can be dampened by comorbid anxiety (Frank et al 2002; 
Gaudiano and Miller 2005), making pharmacotherapy a 
challenge. Despite the high comorbidity, many patients with 
bipolar disorder and a coexisting anxiety disorder do not 
receive appropriately tailored drug therapy. In the STEP-BD 
population mentioned above, only 59% reported pharmaco-
therapy use meeting criteria for “minimally adequate” mood 
stabilizer, regardless of comorbid diagnoses, rapid cycling, 
or bipolar I or II status (Simon et al 2004b). Moreover, even 
though anticonvulsants may have some utility for patients 
with comorbid anxiety, such patients are less responsive to 
therapy than non-anxious patients (Henry et al 2003). Given 
the paucity of existing data and the clear need for improved 
treatment options in this patient subset, it was important to 
examine the effect of quetiapine monotherapy on anxiety 
symptoms in the BOLDER studies.
In the BOLDER I study, mixed model for repeated 
measurements (MMRM) analysis of anxiety symptoms, as 
Figure 4 Least mean squares change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score in outpatients with bipolar I or II disorder and 
rapid or non-rapid cycling (data pooled from BOLDER I and BOLDER II studies; ITT, LOCF).
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rated on the Hamilton Rating Scale for Anxiety (HAM-A), 
revealed that quetiapine monotherapy was associated with 
a rapid and pronounced improvement across individual 
and combined quetiapine treatment groups compared with 
placebo (−10.3 versus −6.7 for combined quetiapine and pla-
cebo groups, respectively), irrespective of baseline severity 
of depression (Hirschfeld et al 2006). Improvements were 
seen in eight of the 14 individual items on the HAM-A scale, 
which included the core items of “anxious mood” (−1.1 
versus −0.5, respectively; p  0.001) and “tension” (−1.1 
versus −0.6 respectively; p  0.001). This improvement 
was replicated in the BOLDER II study, in terms of both 
magnitude and signifi cance (Thase et al 2006).
Improvement in anxiety symptoms was observed in 
the subgroup of bipolar I patients in BOLDER I, in which 
HAM-A total score was signifi cantly improved compared 
with placebo at Week 8 (−10.4 versus −5.1 points, for 
combined quetiapine and placebo groups, respectively; 
p  0.001) (Hirschfeld et al 2006). Within the smaller sub-
set of patients with bipolar II disorder, patients treated with 
active quetiapine or placebo showed comparable improve-
ment in HAM-A total score (−9.8 versus −9.0, respectively). 
Results from subgroup analyses from the BOLDER II trial 
and the pooled data set, not yet available, will be helpful in 
clarifying this unexpected fi nding.
Effects on other secondary outcome 
measures
Quality of sleep
Sleep disturbance is a relatively common occurrence in 
psychiatric patients, with insomnia presenting as a primary 
symptom in 30%–90% of psychiatric disorders. (Becker 
2006) Again, the BOLDER I study was the fi rst to explore 
the impact of quetiapine monotherapy on sleep, using the 
Pittsburgh questionnaire (PSQI) to rate quality of sleep. The 
PSQI is a 24-item questionnaire that includes 19 self-rated 
and 5 items rated by the patient’s bed partner. The instrument 
is used to study sleep quality, latency, duration, effi ciency, 
use of medication, and daytime dysfunction, and assesses 
sleep quality and disturbance in the preceding month.
In BOLDER I, participants showed moderate-to-severe 
sleep disruption at baseline according to the PSQI. At last 
assessment, quality of sleep had improved signifi cantly fol-
lowing treatment with either dose of quetiapine compared 
with placebo (p  0.001) (Endicott et al 2007). Mean values 
for quality of sleep, sleep latency, and sleep duration were 
0.5–0.7 points lower in quetiapine-treated patients than in 
placebo-treated patients (Endicott et al 2007).
Quality of life
To date, dedicated quality-of-life studies in individuals with 
bipolar disorder are relatively sparse, although a number of 
ongoing studies are attempting to redress this imbalance 
in response to increased recognition that recovery should 
be marked by a return to an acceptable quality of life and 
improved functionality for the patient (Michalak et al 2005; 
Mitchell et al 2006; Kasper 2004). The depressive compo-
nent of bipolar disorder is thought to be more detrimental to 
quality of life than the manic component (Vojta et al 2001). 
Furthermore, the degree of functional impairment and loss 
of work productivity experienced by individuals with bipo-
lar depression exceeds that experienced by patients with 
unipolar depression (Vornik and Hirschfeld 2005). There 
is also evidence to suggest that the delayed diagnosis or 
misdiagnosis experienced by many individuals with bipolar 
depression may further impact the quality of life they are 
able to enjoy since early and appropriate intervention can 
drastically enhance not only the symptomatic but also the 
subjective experience of individuals over the long term 
(Kasper 2004).
Thus, any effi cacious medication that can also exert 
positive effects on quality of life in bipolar depression is of 
obvious therapeutic value. Positive effects on health-related 
quality of life may be intrinsically linked with general 
tolerability. If a treatment is well-tolerated, a patient will be 
more likely to become satisfi ed with his treatment regimen. 
The superiority and increasing popularity of the atypical 
antipsychotics over the more conventional antipsychotics 
may derive from their improved tolerability (Vornik and 
Hirschfeld 2005).
The BOLDER I study was the fi rst large-scale investiga-
tion of quetiapine monotherapy in bipolar depression to report 
quality of life as a secondary endpoint (Endicott et al 2007). 
Both BOLDER studies used the short-form version of the 
Quality of Life Enjoyment and Satisfaction Questionnaire 
(Q-LES-Q) to evaluate the impact of quetiapine on health-
related quality of life. This version rates 16 items (physical 
health; mood; work; household activities; social relationships; 
family relationships; leisure-time activity; ability to function 
in daily life; sexual drive, interest and/or performance; eco-
nomic status; living/housing situation; ability to get around 
physically without feeling dizzy or unsteady or falling; vision 
in terms of ability to work or do hobbies; overall sense of 
well-being; medications; and overall life satisfaction and 
contentment during the past week) on a 5-point scale.
Consistent with their disease profi le, BOLDER partici-
pants scored poorly on quality-of-life scores at baseline. 
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Following 8 weeks of treatment with quetiapine, signifi cant 
improvements in Q-LES-Q total score were evident in both 
BOLDER studies (Calabrese et al 2005; Thase et al 2006; 
Endicott et al 2007). In BOLDER I, for example, mean 
Q-LES-Q percentage maximum scores at fi nal assess-
ment (LOCF) were 57.6, 57.4, and 48.1 points for 300 mg 
quetiapine, 600 mg quetiapine, and placebo, respectively 
(Endicott et al 2007). The improvements were signifi cantly 
greater in both quetiapine groups compared with placebo 
(p  0.001) at fi nal assessment. Interestingly, quality-of-
life improvements were positively linked with MADRS 
response and remission status. If a patient responded to 
quetiapine treatment, quality of life also improved, whereas 
MADRS non-response was associated with negligible 
improvement in quality of life.
The Sheehan Disability Scale (SDS), introduced as an 
additional outcome measure for BOLDER II, quantifi ed the 
impact of quetiapine on the interrelated domains of work, 
social life, and family life/home life/responsibilities. At the 
last assessment, the mean improvements in SDS scores from 
baseline were −7.3, −7.9, and −6.0 for 300 mg quetiapine, 
600 mg quetiapine, and placebo, respectively (p  0.05 for 
600 mg quetiapine versus placebo) (Thase et al 2006).
Tolerability profi le
Good tolerability, as rated by physicians and patients alike, is 
integral to the success of any medication strategy. As toler-
ability and treatment adherence tend to worsen as each new 
drug is added to a complex pharmacotherapy regimen, a well-
tolerated monotherapy would be expected to have multiple 
advantages. (Burton et al 2005) Quetiapine monotherapy 
was generally well-tolerated in the BOLDER studies. As 
detailed safety/tolerability data were presented in the source 
publications, (Calabrese et al 2005; Thase et al 2006) only a 
brief summary follows below.
Treatment discontinuations and adverse 
event (AE) incidence
In the BOLDER studies, the proportions of quetiapine-treated 
patients completing the full 8 week treatment protocol was 
similar to that reported for placebo and ranged between 53% 
and 67%. The most common reasons for discontinuation were 
withdrawal of consent, adverse events, loss to follow-up, and 
lack of perceived effi cacy, with attrition due to AEs more 
common among the patients receiving active medication and 
dropouts due to lack of effi cacy more common in the placebo 
groups. None of the serious AEs reported in either BOLDER 
study was considered to have been drug-related.
The majority of AEs were mild-to-moderate in intensity 
and transient in nature. The most common adverse events 
experienced by 5% or more of patients receiving quetiapine 
in both BOLDER studies were dry mouth, sedation, somno-
lence, dizziness, and constipation (Table 1; pooled data from 
BOLDER I and II). Trends in tolerability tended to favor the 
group receiving the lower (300 mg per day) dose, although 
few of these differences were statistically signifi cant.
Weight change
Weight gain in the BOLDER studies was greater among 
the patients receiving active quetiapine. Across studies, the 
pooled weight-gain data showed a mean increase of 1.2 kg 
in the quetiapine 300 mg per day group and 1.5 kg in the 
600 mg per day group, as compared with a gain of 0.2 kg 
in the placebo group. A weight increase of greater than 7% 
was observed in 7.1% of patients receiving the 300 mg/day 
dose of quetiapine, 10.0% receiving the 600 mg/day dose of 
quetiapine, and 2.4% of those receiving placebo.
The weight gain associated with some atypical antipsy-
chotics may often be accompanied by deleterious changes in 
serum lipids and increases in fasting glucose, both of which 
increase the risk for coronary artery disease. It is important 
to note that in the BOLDER trials, the mean change in fast-
ing glucose and lipids with quetiapine was not statistically 
signifi cantly different to that with placebo.
Treatment-emergent mania
As discussed previously, the risk of precipitating a manic 
episode is a major concern when treating bipolar depression 
with traditional antidepressants. Treatment-emergent mania 
affects 20%–40% of individuals with bipolar disorder receiv-
ing long-term antidepressant therapy (Goldberg and Truman 
2003). Since combination therapy may reduce the risk of 
treatment-emergent mania, this is often the treatment approach 
Table 1 Most common adverse events associated with quetiap-
ine treatment in outpatients with bipolar I or II disorder (5% 
patients; data pooled from BOLDER I and BOLDER II studies)
Adverse Quetiapine Quetiapine Placebo
event (%) 300 mg 600 mg (n = 347)
 (n = 350) (n = 348) 
Dry mouth 43.4 43.7 12.7
Sedation 30.9 29.9 8.1
Somnolence 28.6 27.0 6.6
Dizziness 15.4 19.5 6.9
Constipation 10.0 10.6 3.7
Lethargy 5.7 5.2 1.7
Weight increase 2.9 5.7 1.2
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preferred by many psychiatrists (Grunze 2005). Therefore, 
when assessing the tolerability profi le of a single agent, it is 
important to establish the propensity for manic switch.
Data from the BOLDER studies showed a low incidence 
of treatment-emergent mania with quetiapine and placebo. 
Treatment-emergent mania was defi ned as an adverse event 
of mania or hypomania, or Young Mania Rating Scale 
(YMRS) score 16 on any two consecutive visits or at the 
fi nal visit. Data pooled from BOLDER I and II reveal that 
the proportion of patients with treatment-emergent manic 
symptoms was greater in the placebo group (5.2%) compared 
with both quetiapine treatment groups (both 2.9%).
EPS-related AEs
Historically, the atypical antipsychotics have been associated 
with a reduced risk of extrapyramidal symptoms (EPS) within 
the recommended dose ranges compared with their conventional 
counterparts (Pierre 2005). This highly desirable characteristic 
is thought to derive directly from their mechanism of action, 
specifi cally by less avid binding to post-synaptic dopamine 
receptors in the basal ganglia (Seeman 2002; Tort et al 2006).
In the BOLDER trials, no individual specifi c EPS had 
an incidence greater than 5% among patients receiving que-
tiapine and the rate of discontinuation due to EPS was also 
low. The incidence of the abnormal involuntary movements 
that were considered to be EPS was 12.0% with quetiapine 
300 mg per day, 11.5% with quetiapine 600 mg per day, and 
5.5% with placebo. Mean changes in scores from rating scales 
used to assess EPS, the Simpson-Angus Scale and the Barnes 
Akathisia Rating Scale, were low in the quetiapine treatment 
groups and were similar to those reported for placebo.
Long-term effi cacy
One signifi cant limitation of the BOLDER studies is that 
they were limited to only 8 weeks of double-blind therapy 
and patients were withdrawn from study medication at the 
completion of the study. In clinical practice, an effective 
monotherapy of bipolar depression would typically be main-
tained indefi nitely for prophylaxis. To date, the long-term 
effects of quetiapine in bipolar depression have only been 
assessed in a small open-label study (Milev et al 2006), and 
with quetiapine (at doses up to 800 mg/day) being used in 
combination with ongoing antidepressant or mood stabiliz-
ing therapy. A naturalistic 12-month study in 17 patients 
revealed a mean reduction in baseline HAM-D total score of 
55.5% LOCF following the addition of quetiapine to the 
existing treatment regimen (Milev et al 2006). The pro-
portion of patients (n = 13) achieving a 50% reduction in 
HAM-D
17
 total score was high, at 76.5%. Although these 
preliminary data are encouraging, larger controlled stud-
ies are required to extend these long-term fi ndings and to 
examine the long-term effects of quetiapine monotherapy in 
particular. Maintenance studies with quetiapine in bipolar 
disorder are currently under analysis. The impact of longer 
term quetiapine therapy on weight and other metabolic 
indices will be of considerable interest.
Relative effi cacy
Another limitation of the BOLDER studies is that neither 
study included an active comparator. Now that effi cacy has 
been established, comparative studies are needed, both versus 
conventional mood stabilizers such as lithium and valproate, 
and the olanzapine – fl uoxetine combination (OFC) (the 
only other treatment strategy now approved for treatment 
of bipolar depression). Some would argue that head-to-head 
comparisons versus lamotrigine also are needed. Although 
the acute phase effi cacy of lamotrigine has not yet been estab-
lished by a series of unequivocally positive RCTs, it is widely 
used by clinicians for treatment of both bipolar I and bipolar 
II depression and there is, at the least, evidence suggestive 
of effi cacy in the literature (Calabrese et al 1999; Frye et al 
2000). In the only study to directly compare lamotrigine and 
OFC, trends favoured the latter drug on effi cacy measures, 
although tolerability indices clearly favoured lamotrigine 
(Brown et al 2006). In addition to studies of quetiapine as a 
monotherapy, its utility in combination with other relevant 
therapies, both antidepressants and conventional mood sta-
bilizers, warrant evaluation.
Is quetiapine a mood stabilizer?
There is currently a lack of consensus surrounding the label 
“mood stabilizer,” but generally, if an agent shows effi cacy 
in treating both acute manic and depressive symptoms and 
is also effective in the prevention of recurrences, it can be 
considered as such (Bauer and Mitchner 2004; Goodwin and 
Malhi 2007). Currently, no one treatment adequately fulfi lls 
the “ideal” mood stabilizer criteria, although the popular view 
is that lithium comes closest to doing so (Sachs 2005). The 
emergence of quetiapine, with its bimodal activity against 
bipolar mania and depression, may qualify as a mood stabi-
lizer in its own right (Vieta 2005; Sachs 2005).
The defi ning criteria for a mood stabilizer mentioned ear-
lier omit other desirable characteristics like good tolerability, 
which tend to become more relevant once effi cacy has been 
established (Bauer and Mitchner 2004). Clearly, if a treatment 
is well tolerated, then adherence, quality of life, and caregiver 
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benefi ts will also improve. So if the antidepressant effi cacy 
of quetiapine derived from BOLDER and its proven ability 
in improving manic symptoms from earlier studies place 
quetiapine monotherapy in a strong position as a potential 
mood stabilizer, its tolerability profi le is favorable enough 
to permit fi rst line use if syndromal severity is suffi cient to 
justify prescription of an atypical antipsychotic. The low rate 
of treatment-emergent mania gives quetiapine an obvious 
advantage over the combination of a mood stabilizer and a 
traditional antidepressant. Nevertheless, the strong perform-
ance of quetiapine in patients with a history of rapid cycling 
observed in the BOLDER studies does warrant prospective 
replication before this medication can truly be considered 
a treatment of choice for this clinically challenging pres-
entation of bipolar disorder. Although longer-term data in 
bipolar disorder are needed, results of the BOLDER studies 
are reassuring that a large majority of patients will not gain 
a meaningful amount of weight during acute-phase therapy. 
Accompanying quetiapine-induced improvements in qual-
ity of sleep, functionality, and health-related quality of life 
will impact not only the patient, but the family members or 
caregivers who surround them. Ultimately, caregiver percep-
tion and not just patient perception will dictate the success of 
quetiapine as a mood-stabilizing treatment option. Dedicated 
studies in this area are awaited with interest.
Conclusions
The BOLDER studies demonstrated that two doses of quetiap-
ine monotherapy – 300 mg and 600 mg – prescribed at bedtime 
were rapidly effective and generally well tolerated in bipolar 
depression. The antidepressant effi cacy of quetiapine was 
found in both bipolar I and bipolar II depression and extended 
to patients with high levels of anxiety as well as those with a 
history of rapid cycling. Quetiapine was also associated with 
signifi cant improvements in health-related quality of life, 
improvements that were intrinsically linked to its antidepres-
sant effi cacy. Comparative trials are now needed to help to rank 
quetiapine therapy among the group of other widely regarded 
fi rst-line options, and long-term data from controlled studies 
of patients treated for bipolar depression are also needed to 
ensure that these effects are durable and that tolerability is 
acceptable across months or even years of therapy.
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